Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial

被引:70
作者
Gibson, C. Michael
Kirtane, Ajay J.
Murphy, Sabina A.
Rohrbeck, Steve
Menon, Venu
Lins, Jeffrey
Kazziha, Samer
Rokos, Ivan
Shammas, Nicolas W.
Palabrica, Theresa M.
Fish, Polly
McCabe, Carolyn H.
Braunwald, Eugene
机构
[1] Harvard Univ, Sch Med, TIMI Study Grp, Div Cardiovasc,Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Univ N Carolina, Charlotte, NC 28223 USA
[5] Tristate Med Grp, Fortwayne, IN USA
[6] Mt Clemens Gen Hosp, Mt Clemens, MI USA
[7] Northridge Hosp, Northridge, CA USA
[8] Midwest Cardiovasc Res Fdn, Davenport, IA USA
[9] Millennium Pharmaceut Inc, Cambridge, MA USA
关键词
D O I
10.1016/j.ahj.2006.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Early restoration of epicardial flow before primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) has been associated with improved clinical outcomes. Methods We hypothesized that early administration of the glycoprotein IIb/IIIa inhibitor eptifibatide in the emergency department (ED) would yield superior epicardial flow and myocardial perfusion before primary PCI compared with initiating eptifibatide after diagnostic angiography in the cardiac catheterization laboratory (CCL). Three hundred forty-three patients with STEMI were randomized to either early ED eptifibatide (n = 180) or CCL eptifibatide (n = 163). Results The primary end point (pre-PCI corrected TIMI frame count) was significantly lower (faster flow) with early eptifibatide (77.5 +/- 32.2 vs 84.3 +/- 30.7, P = .049). The incidence of normal pre-PCI TIMI myocardial perfusion was increased among patients treated in the ED versus CCL (24% vs 14%, P = .026). There was no excess of TIMI major or minor bleeding among patients treated in the ED versus CCL (6.9% [12/174] vs 7.8% [11/142], P = NS). Conclusion A strategy of early initiation of eptifibatide in the ED before primary PCI for STEMI yields superior pre-PCI TIMI frame counts, reflecting epicardial flow, and superior TIMI myocardial perfusion compared with a strategy of initiating eptifibatide in the CCL without an increase in bleeding risk.
引用
收藏
页码:668 / 675
页数:8
相关论文
共 27 条
[21]  
*STAT CORP, 2004, STAT STAT SOFTW PROG
[22]   Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. [J].
Stone, GW ;
Grines, CL ;
Cox, DA ;
Garcia, E ;
Tcheng, JE ;
Griffin, JJ ;
Guagliumi, G ;
Stuckey, T ;
Turco, M ;
Carroll, JD ;
Rutherford, BD ;
Lansky, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) :957-966
[23]   Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction - Analysis from the primary angioplasty in myocardial infarction trials [J].
Stone, GW ;
Cox, D ;
Garcia, E ;
Brodie, BR ;
Morice, MC ;
Griffin, J ;
Mattos, L ;
Lansky, AJ ;
O'Neill, WW ;
Grines, CL .
CIRCULATION, 2001, 104 (06) :636-641
[24]   Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty -: Results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study [J].
van den Merkhof, LFM ;
Zijlstra, F ;
Olsson, H ;
Grip, L ;
Veen, G ;
Bär, FWHM ;
van den Brand, MJBM ;
Simoons, ML ;
Verheugt, FWA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (06) :1528-1532
[25]   FT -: Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor:: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial [J].
van't Hof, AWJ ;
Ernst, N ;
de Boer, MJ ;
de Winter, R ;
Boersma, E ;
Bunt, T ;
Petronio, S ;
Gosselink, ATM ;
Jap, W ;
Hollak, F ;
Hoorntje, JCA ;
Suryapranata, H ;
Dambrink, JHE ;
Zijlstra, F .
EUROPEAN HEART JOURNAL, 2004, 25 (10) :837-846
[26]  
ZEYMER U, 2005, EUR J HEART
[27]   Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty [J].
Zorman, S ;
Zorman, D ;
Noc, M .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (05) :533-+